Isoniazid is a first-line antimycobacterial drug used in combination regimens for active tuberculosis and in preventive treatment for latent tuberculosis infection in selected populations. Labeling emphasizes resistance prevention and hepatotoxicity monitoring risk management. It is a long-established human prescription antibacterial medicine.
Three advances in TB diagnostics: a portable $300 device delivering results in 30 minutes, a Quick DNA kit detecting drug resistance in 5 minutes, and an ultrasensitive test finding TB DNA in 12-16% of hospitalized US patients.
A vaccine and two novel tuberculosis treatments are advancing through Phase III trials, marking renewed momentum in TB research. Tuberculosis claims over 1.25 million lives annually with 10.6 million new cases in 2023, while current treatments face challenges of high pill burden, toxicity, and rising resistance.
BioVersys has dosed the first patient in a Phase 2b trial evaluating alpibectir-ethionamide (AlpE) in combination with first-line TB drugs, following promising Phase 2a results published in the New England Journal of Medicine.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07595042 |
A Trial of Stratified Patient-Centered Treatment Regimens for Active TB (SPECTRA-TB) |
NOT_YET_RECRUITING | PHASE2 |
| NCT06192160 |
Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis |
RECRUITING | PHASE2 |
| NCT03730181 |
Tuberculosis Clinical Trials Consortium Study 35 |
COMPLETED | PHASE1/PHASE2 |
